EMA’s Clinical Trials Guidance for Enhanc...

By HEOR Staff Writer

March 9, 2026

The European Medicines Agency (EMA) has released draft clinical trials guidance for public consultation from 4 March to 30 April 2026. This
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Fi...
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Pre...
Urgent Call for Enhanced Precision Oncology Access in Europe
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market A...